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OBJECTIVE — We compared inﬂammatory markers among women with a history of gesta-
tional diabetes mellitus (hGDM), women with diagnosed diabetes, and unaffected women in a
population-based sample.
RESEARCH DESIGN AND METHODS — We conducted cross-sectional analyses of
6,346 nonpregnant women in the Third National Health and Nutrition Examination Survey
(1988–1994).WomenwereclassiﬁedashavinghGDM(n87),diagnoseddiabetes(n244),
or neither condition (n  6,015). Inﬂammatory markers included ferritin, leukocyte count, and
C-reactive protein levels.
RESULTS — After adjustment, women with diagnosed diabetes had the most marked differ-
ences in inﬂammatory markers compared with unaffected women. Differences between unaf-
fected women and women with hGDM were minimal.
CONCLUSIONS — Women with diagnosed diabetes have less favorable inﬂammation pro-
ﬁles than unaffected women and greater ferritin levels than women with hGDM. After adjust-
ment, women with hGDM who have not developed diagnosed diabetes have inﬂammation
proﬁles similar to those of unaffected women.
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W
omen with a history of gesta-
tional diabetes mellitus (hGDM)
are at increased risk for future
glucose intolerance, and this risk may be
associated with inﬂammation (1–4). The
association has not been examined in
population-based studies and may not be
robust after adjustment for BMI (1–4).
UsingdatafromthethirdNationalHealth
and Nutrition Examination Survey
(NHANES III), a population-based cross-
sectional study, we compared inﬂamma-
tory markers among unaffected women
versus women with hGDM and women
with diagnosed diabetes.
RESEARCH DESIGN AND
METHODS
The sampling strategy and data collection
methods for NHANES III have been pre-
viously described (5). We excluded
women who were currently pregnant,
had missing data regarding pregnancy
status, or had previous diabetes or hGDM
diagnoses, for a total sample of 6,346
women.Womenwereclassiﬁedashaving
diagnosed diabetes if they reported a di-
agnosis of diabetes outside of pregnancy,
as having hGDM if they reported having a
diagnosis of diabetes made only during
pregnancy, and as unaffected if they did
not have hGDM or diagnosed diabetes.
Therefore, the categories of unaffected
women (n  6,015), women with hGDM
(n  87), and women with diagnosed di-
abetes (n  244) were mutually exclu-
sionary. In NHANES III, undiagnosed
diabetes was assessed in a subsample of
nondiabetic individuals who were ran-
domly assigned to a morning fasting
examination.
Information on demographic and
behavioral factors was collected by in-
terview (5). The poverty index was cal-
culated as the poverty-to-income ratio
(6). Measurements of height, weight,
and waist circumference were per-
formed in a standardized manner. Leg
lengthwascalculatedbysubtractingsit-
ting height from standing height (7).
Measurement procedures for inﬂamma-
tory markers for ferritin (8), leukocytes
(9), and C-reactive protein (CRP) (6) in
the NHANES III have been previously
described.
Statistical analysis
All analyses accounted for the multistage,
stratiﬁed, cluster-sampling design of
NHANES III by using survey sample
weights. We conducted tests for trend
across unaffected women, women with
hGDM, and women with diagnosed dia-
betes across exposure variables. We cal-
culated predicted marginal probabilities
and 95% CIs in multivariate models. In a
sensitivity analysis, we excluded women
who had fasting glucose 126 mg/dl and
who were also classiﬁed as having hGDM
or as unaffected, but results did not
change. We restricted analyses to only
parous women, but results did not
change. Statistical analyses were con-
ductedusingSUDAAN9.0(ResearchTri-
angle Institute, Research Triangle Park,
NC).
RESULTS— Women with diabetes
were signiﬁcantly older than women with
hGDM and unaffected women (46 vs. 32
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and more often reported non-Hispanic
blackethnicity(P0.0001),afamilyhis-
tory of diabetes (P  0.0001), the least
favorable poverty-to-income ratio (P 
0.0036), the fewest number of alcoholic
beverages per day (P  0.0001), and the
greatest waist circumference (P 
0.0001). Waist circumference increased
across unaffected women, women with
hGDM, and women with diabetes from
85.9 to 92.4 to 103.2 cm, respectively
(P  0.0001). Few women were nullipa-
rous; all of the women in the hGDM and
diabetic groups and 91% of unaffected
women had at least one delivery. Women
with diabetes had the highest ferritin
measurements compared with women
with hGDM and unaffected women
(135.1 vs. 59.4 and 62.7 ng/ml, respec-
tively;P0.0001),thehighestleukocyte
counts (8.4 vs. 8.0 and 7.2 cells/ml, re-
spectively; P  0.0001), and the highest
CRP levels (0.88 vs. 0.51 and 0.40 mg/l,
respectively; P  0.0012).
When we adjusted for patient covari-
ates, the most striking differences were
seen between women with diabetes and
unaffected women. After adjustment for
demographic and behavioral factors (Ta-
ble 1, model 1), women with diabetes had
greater ferritin, leukocyte, and CRP mea-
surements than unaffected women. After
further adjustment for waist circumfer-
ence (Table 1, model 2), women with dia-
betes had greater inﬂammatory marker
levelsthanunaffectedwomen,butthedif-
ferences in CRP were no longer signiﬁ-
cant. As in unadjusted analyses, we
observed no signiﬁcant differences in in-
ﬂammatory markers between unaffected
womenandwomenwithhGDM.Women
with hGDM had lower inﬂammatory
markers than women with diabetes, but
the differences were statistically signiﬁ-
cant only for ferritin, not for CRP or leu-
kocyte counts.
CONCLUSIONS— This population-
based cross-sectional study suggests that
differences in inﬂammatory markers are
greatest between women with diagnosed
diabetes and unaffected women. Ferritin
levelsdistinguishedwomenwithdiabetes
from unaffected women and women with
hGDM before and after adjustment for
other risk factors, but ferritin did not dif-
fer signiﬁcantly between unaffected
women and women with hGDM.
Our ﬁndings are consistent with re-
sults from previous studies of women
with hGDM versus unaffected women
that have not shown robust associations
after adjustment of BMI or other markers
of adiposity (1–4). Our ﬁndings are also
consistentwithstudiesthatcomparedun-
affectedwomenandwomenwithdiabetes
that found more robust associations (10).
This study has several limitations.
NHANES III was cross-sectional and may
not reﬂect disease progression in individ-
uals. It is possible that the relationship
between inﬂammation and hGDM would
have been stronger had we been able to
distinguish which women would go on to
develop diabetes and if we were able to
adjust for time since delivery. It is also
possible that examination of other mark-
ers with greater discrimination would
have shown an association. There may
havebeenunmeasuredconfoundingwith
other inﬂammatory conditions not in-
cluded in our analysis. Finally, the num-
ber of women with hGDM was greater
than in most other reports, though still
small, leading us to report group differ-
ences only when the 95% CIs were mutu-
ally exclusive.
In conclusion, the differences in in-
ﬂammatory markers between women
with hGDM and unaffected women were
muchsmallerthanthosebetweenwomen
with diabetes and unaffected women.
Prospective longitudinal studies using in-
ﬂammatorymarkerswithgreaterdiscrim-
ination may elucidate how inﬂammation
progresses in women who develop GDM
and then diabetes after delivery.
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